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Abstract
Despite all recent treatment advances and the worldwide decline in the incidence rate, gastric cancer (GC) remains an ongoing 
global health challenge and one of the major leading causes of cancer-specific deaths, particularly in high-incidence regions 
including Iran. Since GC is often diagnosed in advanced stages, the best action may be to enable early diagnosis of the disease or 
even prevent it in the first place through identification and control of the underlying risk factors. Endoscopy, as the gold standard 
method, is both expensive and invasive, making it an unfavorable device in this regard. Therefore, it is crucial to implement a reliable 
region-specific screening and surveillance program to identify high-risk individuals with more efficient screening modalities. Here, 
in addition to a review of current GC knowledge, we presented the data of newly-established Population-based Cancer Registries 
(PBCRs) in Iran. Our assessment confirmed earlier reports of a very high GC incidence rate in the northwestern and northern 
provinces of Iran, most notably Ardabil. Along with the important role of conventional risk factors such as Helicobacter pylori (HP) 
infection and high dietary intake of salt, of more interest, we highlighted new region-specific risk factors, namely hookah, and 
opium. In conclusion, it seems the best results in reducing GC incidence and mortality rates on larger scales arise from modifying 
behavioral and environmental risk factors and advancing genetic and molecular biomarkers in order to supersede endoscopy. 
Regular endoscopic screening and antibiotic chemoprophylaxis against HP are still more appropriate in high-risk groups with 
specified criteria.
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Gastric cancer (GC) is the fifth most frequently diagnosed 
cancer and the third leading cause of cancer-specific 
mortality worldwide.1 Currently, 18.08 million new cases 
of cancer are reported globally each year; of these, about 
1.03 million (5.7%) are GC. Also, GC is responsible for 
about 783 000 (8.2%) out of 9.56 million cancer-related 
deaths across the world every year.2 However, there exists 
a remarkable diversity in the geographical distribution 
of GC incidence and mortality rates across populations 
(Figure 1).2 With 75% of all new cases and deaths of GC, 
Asia is considered a high-incidence area. Despite the 
downward trend in the incidence and mortality rates of 
GC over the past decades (Figure 2),3-8 not only is it still 
among the top leading causes of cancer-related deaths, but 
will also maintain its position in the coming years.9 
Since GC is either asymptomatic or may present with 
mild non-specific gastrointestinal symptoms in its early 
stages, it is often diagnosed in advanced stages and 
consequently, no therapeutic or survival benefit is acquired 
from conventional surgery or chemo/radiotherapy.10 
Unfortunately, this leads to a poor prognosis for this 
disease.11 For example, numerous studies have shown that 
more than 80% of Iranian GC patients have been diagnosed 
in advanced stages of disease (predominantly stage IV) 
and their 5-year survival rates remain no better than 29.7% 
(ranging from 0.8% to 29.7%),12-14 even those treated with 
surgery.15,16 Therefore, it is essential to implement an 
efficient screening and surveillance program to detect GC 
in its early stages or even to prevent it from happening 
at the very beginning through identification and control 
of modifiable risk factors.17,18 PBCRs are powerful tools to 
provide the required data in this context.
In this review, we focus on the current epidemiological 
aspects of GC in Iran, the attributed region-specific risk 
factors, as well as screening modalities and preventive 
measures.
Development of Population-Based Cancer Registries in 
Iran
Over the past few decades, the tremendous socioeconomic 
transition in developing countries has resulted in a large 
epidemiological data gap. In order to achieve reliable 
nationwide epidemiological data, establishing cancer 
registries is the first essential step to take.19,20 
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made the first attempts to organize cancer reporting by 
the establishment of Cancer Institute.21 Then in 1986, a 
pathology-based cancer registry was officially established 
in Iran with the joint collaboration of TUMS, the 
Iranian Ministry of Health and Medical Education and 
International Agency for Research on Cancer (IARC).21 
In the beginning, the program was launched in a few 
high- and low-incidence regions and was then expanded 
to cover more populations. At maximum, only 81% of 
all estimated new cancer cases were covered in the latest 
series of pathology-based statistics published in 2005.22 
In order to attain a thorough GC epidemiological map, 
the Digestive Disease Research Institute (DDRI) of 
TUMS initiated a large population-based study named 
“Gastric and Esophageal Malignancies in Northern Iran” 
(GEMINI) for the first time in selected provinces during 
the early 2000s.23-25 Since Population-based Cancer 
Registry (PBCR) seeks data from any source in which 
cancer cases may be diagnosed or treated (such as hospital 
records in practice, cytopathological reports in diagnostic 
departments, or even death certificates when possible),26 
it was more comprehensive than former pathology-
based cancer registries in providing data for a better 
understanding of diseases and contributing to cancer 
Figure 1. Worldwide Geographical Variation in The Age-Standardized Incidence Rate (ASR) of Gastric Cancer, Reproduced from the 
























Figure 2. Time Trend of the Age-Standardized Incidence Rate of Gastric Cancer in (a) High- (South Korea and Japan) Versus (b) Low- (USA 
and UK) Incidence Selected Countries. Reproduced from the International Agency for Research on Cancer (IARC). As seen, high-incidence 
regions have experienced a slower decline.
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prevention plans. These encouraged us to shift from 
pathology-based to PBCR nationwide. Therefore, in the 
early 2010s, the Iranian national PBCR was developed and 
today, it covers about 100% of the Iranian population.23 
Comparing the Iranian national PBCR data quality 
indicators with those from other high-quality cancer 
registries (microscopic verification of 68.28%, death 
certification only of 12.99% and unknown primary site of 
5.62%), our quality indices are within acceptable ranges.
In the following, we will present our latest knowledge 
about GC in Iran greatly obtained from the Iranian 
national PBCR. 
Epidemiology of Gastric Cancer in Iran
Like many other Asian countries, Iran has high incidence 
and mortality rates of GC. In a recent study by Roshandel 
et al, GC ranked the first most common cancer in males 
(age-standardized incidence rate [ASR] = 21.2) and the 
third in females (ASR = 9.4).23 More importantly, it is the 
first cause of cancer-related deaths overall.2 In line with 
the global diversity in GC distribution, Iran itself has a 
wide variation in the incidence and mortality rates across 
different provinces (Figure 3).27,28 Most northern and 
northwestern regions of Iran are hotspots for GC. The risk 
gradient falls towards the southern regions of the country.29 
For instance, while in Ardabil (a northwestern province) 
the ASR value was 48.4 in men and 20.6 in women, the 
corresponding figures were 7.1 and 5.3 in Hormozgan (a 
southern province), respectively.23 The same pattern is 
also seen in the west Asian population, so that northern 
countries like Iran and Turkey suffer more from upper 
gastrointestinal malignancies.30 These discrepancies may 
be justified by the heterogeneous geographical distribution 
of GC attributed risk factors, which are discussed further.
Contrary to the recent global decline, Iran has experienced 
a slight increase in the incidence rate of GC.27,31 However, 
we speculate that this observation may be due to prior 
misclassification of gastric cardia cancers as esophageal 
cancers.8,32 With advances in diagnostic strategies, today 
the diagnosis of GC has improved.33
Risk Factors of Gastric Cancer in Iran
The pattern of GC distribution demonstrates its robust 
association with environmental, racial and geographical 
factors. The prevalence of GC risk factors and their 
contributing attributable risks differs across high- and 
low-incidence populations.34 Given that South Korea has 
the highest (ASR = 39.6) and the UK one of the lowest 
(ASR = 3.9) rates of incidence in the world,1 stating some of 
their statistics outlines this fact appropriately. A systematic 
review has reported very different Helicobacter pylori (HP) 
prevalence in two countries; 54.8% in South Korea, and 
27% in the UK, revealing a two-fold difference.35 Again, 
it has been estimated that the prevalence of smoking and 
its population attributable fraction for GC in males were 
65.1% and 28.8% in South Korea and 27% and 14.3% in 
the UK, respectively.36
Another excellent example in this regard is the average 
amount of dietary salt intake, which is 13 g/d in South 
Korea versus 9 g/d in the UK.37 Furthermore, it was 
estimated that a relatively high proportion of GCs would 
be prevented by increasing the consumption of fruits and 
vegetables up to the theoretical minimum-risk exposure 
levels (300 and 400 g/d, respectively), defined by the 
Global Burden of Disease.38 
Thus, in order to establish an efficient, cost-effective 
strategy against GC, identifying and incorporating these 
risk factors in the plan is pivotal. Correspondingly, we have 
also addressed a few of our national and local challenges 
in the following.
Helicobacter pylori
It has been well-established that the current or past history 
of HP infection is associated with an increased risk of GC.39 
Figure 3. The Estimated Age-Standardized Incidence Rate of 
Gastric Cancer in Different Provinces of Iran, Retrieved from Iran’s 
Latest Population-Based Cancer Registry Study.
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In the largest retrospective cohort study, Bae et al observed 
that the risk of developing GC in the non-eradication 
group was significantly higher than HP-negative 
individuals (hazard ratio [HR] = 4.12) and eradication 
groups (HR = 2.73) in a time frame of 6.4 years.40 Similar 
to other high-incidence areas, the prevalence of HP 
among the Iranian population, both adults and children, 
is very high.41-43 For example, in a population-based study 
in the Ardabil province, about 89% of adults aged 40 or 
older had positive HP test.25 Nouraie et al declared that 
these high figures are correlated to the family education, 
low socioeconomic status and poor sanitary conditions.43 
Additionally, the acquisition age of HP infection is very 
low in Iran. In a study in Shiraz, in southern Iran, 82% 
of 9-month-old infants and 98% of children aged 2 years 
were infected with HP.44
Special virulence factors of HP infection, namely 
cytotoxin-associated gene A (CagA) and vacuolating-
cytotoxin A (VacA), are more commonly found in the 
stomach of patients with GC.45 In Iran, CagA positive 
strains are the most common strains among HP-infected 
subjects. The prevalence varies between 66% and 91% 
in different populations.46-49 The contribution of CagA 
positive HP to an excess cancer risk is yet to be studied. 
VacA i1-type strains, on the other hand, were shown to 
have a stronger association with gastric adenocarcinoma 
than, and independently of, CagA status.50
Despite the high prevalence of HP infection in Iran, 
there is still uncertainty about its contribution to excess 
risk of GC. Comparing the prevalence of HP infection in 
three distinct areas of Iran with low to high GC prevalence, 
we found no significant difference between the rates of 
HP across these regions.10 This means that not all of the 
HP-infected subjects develop GC, which highlights the 
necessity of the concurrent presence of both environmental 
and host-related factors. As a confirmation, our study on 
immigrants from high-(Iran) to low-(Canada) incidence 
regions indicated a downtrend in GC incidence among 
them, notably in the second and third generations.51
In addition to HP, infection with Epstein-Barr virus 
(EBV) is thought to be associated with 10% of all GCs.52 
Nevertheless, no significant difference was seen between 
the outcomes of the infected and non-infected patients; it 
was even shown that the presence of EBV has a favorable 
impact on GC patients’ survival.53,54 Considering the very 
high infection rate among the general population and 
many unidentified confounding factors, the real image of 




The topmost influential and well-recognized dietary risk 
factor of GC is excessive salt intake, which not only causes 
atrophic gastritis, but also facilitates HP colonization.55,56 
In a population-based study conducted in Ardabil, it was 
shown that people with a preference for higher salt intake 
and some traditionally preserved salted foods, especially 
meats and pickles, were at about 3 times greater risk of 
GC.57 Based on our study in the same region, 70.6% of 
GC cases were attributable to excess salt intake (>6 g/d).56 
In a large systematic analysis of 24 hours urinary sodium 
excretion and dietary surveys, the age-standardized 
estimate of “sodium” intake in Iran was 4.02 g/d in 2012, 
which is equivalent to ~10 g/d “salt” intake as multiplied 
by 2.5. This figure is much higher than the 5 g/d limit of 
“salt” intake recommended by the WHO.58
2. Low Levels of Fresh Fruits and Vegetables
A diet with an insufficient level of antioxidants is a 
common risk factor of GC.59 Accordingly, diets containing 
vitamin C, E, A, and carotenoids have an inverse 
relationship with GC development.60,61 That is why lower 
levels of fresh fruits and vegetable intake, which are rich in 
antioxidants and fibers, increase the risk of GC.38,62 Citrus 
fruits and white vegetables are the most renowned in this 
category.38,63 
In Iran, Vitamin E was shown to have a strong protective 
effect only on the cardia subgroup of GC. On the other 
hand, an inverse association was observed for vitamin C in 
all GC subtypes.64 In a population-based case-control study 
in Ardabil, Pourfarzi et al highlighted the importance of 
consuming citrus fruits (OR = 0.31) for GC prevention.57 
Later in the same region, the diet-GC association was 
assessed using a food frequency questionnaire.64 It was 
shown that fruits and vegetables consumption (OR = 0.72), 
particularly raw vegetables (OR = 0.12), was protective 
against GC. Both studies emphasized especially the 
protective effect of allium vegetables (garlic and onion) 
against GC and this was consistent with the results of 
a review by Guercio et al65 We also found that 31.5% of 
GC cases were attributable to a low intake of fruits and 
vegetables (<400 g/d) in Ardabil.56
3. Preserved Food
Consumption of any kind of preserved food, including 
salted, smoked, pickled, cured, or processed, could be 
responsible for GC.57 This is probably due to the loss of 
vitamins and antioxidants as well as increased nitrite 
concentrations found in these products.66 New methods of 
food storage such as refrigeration could indirectly decrease 
the risk of GC through reducing the intake of preserved 
food. This reduction could reach 30%, according to a 
meta-analysis of 12 observational studies.67 Iranians also 
used to traditionally preserve meat and vegetables, namely 
ghorme and pickles, from years ago. Pakseresht et al from 
Ardabil also observed an estimated risk reduction of 25% 
for every 10 years of refrigerator use.64 
4. Meat
Diets rich in red meat seem to be connected with high-
incidence rates of GC.68 In contrast, the increase in white 
meat consumption, especially fish meat, may reduce the 
risk of GC.68 We have also observed this fact in several 
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studies conducted in high-risk regions in Iran. With red 
meat consumption, one might be 2 to 3 times more likely 
to develop GC, while with regular fish meat intake, the 
risk of GC could be reduced by one-third to one-fifth.57,69
5. Other Dietary Components
Several other risk and protective nutrients are introduced 
in the literature, as well. Overall, prudent healthy diets, 
like the Mediterranean diet, which are “rich” in fruits and 
vegetables, cereals, beans, “moderate” in fish, white meat, 
eggs, and alcohol and “low” in salt, dairy products, red and 
processed meat, sugar, and fat can prevent GC incidence 
in the long term.70
Interestingly, in a population-based case-control study 
in Ardabil, Pourfarzi et al reported that GC development 
was attributed to an increase in the frequency of dairy 
products intake (OR = 2.28).57 Besides, different types 
of dairy products were discussed in detail in a study by 
Somi et al., which indicated that high-fat milk, yogurt and 
special types of cheeses (khiki and koze) increased the risk 
of GC.71 However, the cause is unknown; the association 
may be confounded by other environmental risk factors, 
particularly in rural areas where dairy consumption is 
higher than the urban population. 
Another potent contributor to GC is suspected to be 
the habit of drinking strong and hot tea in northwestern 
and northern parts of Iran, similar to esophageal cancer 
(OR = ~2.5).57 Food groups containing fat and sugar and 
mixed nuts have also displayed a clear association with 
non-cardia GC.64
Low doses of capsaicin (in hot red chili pepper), 
flavonoid (in leafy vegetables and onion), zinc, iron, 
selenium, and folate are some of the examples of this 
sort.64,72-75 The proportion of the population with selenium 
deficiency was 71% in Ardabil, which may partially 
explain the high rates of GC.73 
Smoking, Opium, and Hookah
Tobacco smoking (both cigarette and hookah) and opium 
abuse are further risk factors (OR = 1.8-2.5) having a 
direct relationship with GC development.56,76-78 Hookah is 
a traditional instrument for tobacco smoking in western 
Asia. Considering the global rise in hookah smoking due 
to misconceptions about its safety compared to cigarettes 
as well as the increase in opium abuse, it is essential to 
perform studies to evaluate their nature and mechanism 
of action in GC pathogenesis, and so to notify the public 
at the primary prevention level.78 In a recent study, we 
demonstrated hookah as a neglected risk factor (OR = 2.4) 
not only for GC, but also for precancerous lesions, which 
may eventually progress to GC.56 Comparable results 
were also found for opium abuse.56,77 With an attributable 
fraction of 62%, tobacco smoking was the second most 
preventable risk factor of GC after HP infection. Opium 
was also strongly associated with GC (OR = 3.2), but its 
lower prevalence made it responsible for 8.3% of cases.56
Family History and Hereditary Factors
GC appears to be clustered in certain families.79 A 
meta-analysis of 15 case-control studies affirms this 
relationship with 1.5-3.5-fold risk ratios for familial 
GC.80 A study by Setia et al showed that 10% of all GCs 
have familial clustering and only 1-3% of cases are 
promoted by hereditary factors.81 It is worth mentioning 
that exceptionally, patients with a specific type of GC, 
hereditary diffuse type, are independent of HP infection 
status and also show an unclear relationship with other 
environmental risk factors. In Iran, gastric precancerous 
lesions, like atrophy and dysplasia, were more prevalent 
in first-degree relatives of patients with known GC.82 
Furthermore, the risk of developing GC was estimated to 
be increased by over 2-folds for these groups.83
Precancerous Lesions
Unlike most risk factors that are mainly applicable to 
classic non-cardia cancer, both severe gastric atrophy 
(OR = 3.92) and frequent gastroesophageal reflux disease 
symptoms (OR = 10.08) have been significantly associated 
with increased risk of cardia GC in Ardabil.84 Other well-
documented pathological stages are gastric ulcer, gastric 
atrophy, intestinal metaplasia and dysplasia, and gastric 
polyps.
Suggested Screening and Surveillance Interventions
The insidious nature of GC and all mentioned regional 
differences leave us no choice but to pursue an efficient 
region-specific screening and surveillance strategy to 
identify high-risk individuals and enable early cancer 
detection.
Endoscopy
Endoscopy has been shown to be the gold standard 
screening-diagnostic method in different studies. 
Nationwide GC screening programs with regularly 
targeted endoscopy have been conducted in two high-
incidence eastern Asian countries, Japan and South Korea, 
and led to a marked decrease in the burden of the disease.85 
In Japan, both endoscopic and photofluorographic 
screenings are recommended over the age of 50 every 2–3 
years.86 The Japanese screening program has identified 
25% of all GCs; of these, about 60% of cases are diagnosed 
in early stages with much better response to therapy.87 In 
South Korea, biennial screening through endoscopy or 
upper gastrointestinography is done for individuals at the 
age of 40 and older.88 Similar to Japan, this program has 
also resulted in the identification of about 46% to 67% of 
GCs in the early stages with favorable outcomes.89
On the other hand, the widespread use of endoscopy 
as a screening modality has been found as an unpleasant, 
expensive, hard-to-reach, and invasive approach.85,90 So, 
the question persists regarding those who are the most 
appropriate candidates for multiple short-interval regular 
endoscopic exams. For example, it has been demonstrated 
in various studies that the precancerous lesions of intestinal 
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metaplasia (IM) are associated with an increased risk of 
GC, which suggests regular endoscopy for IM patients’ 
surveillance in order to reduce GC incidence56,91-93 
However, these results are based on a limited number of 
subjects, which may yield negligible positive predictive 
value, and also there is no evidence from randomized 
studies to support surveillance of IM.94 So, endoscopic 
screening of younger patients with IM, even in high-
incidence areas, might not be efficient or cost-effective. 
Altogether, based on the current GC screening programs 
and our point of view, we tend to suggest that definite high-
risk individuals of 50 years of age and above, particularly 
from a high-risk region, might benefit more from frequent 
endoscopy surveillance every 2–3 years.
Non-invasive Biomarkers
Currently, there is an increasing interest in using reliable, 
convenient, non-invasive tools to detect precancerous 
lesions or early stages of GC of individuals at-risk. The use 
of biomarkers seems to fulfill this goal.95 So far, many of 
the recognized tumor markers such as carcinoembryonic 
antigen and carbohydrate antigen 19-9 (CA19-9), which 
are neither highly sensitive nor specific, are just useful 
for monitoring tumor progression and recurrence.96,97 
In the following, some of the promising biomarkers for 
screening are reviewed:
Pepsinogen: In a cascade, HP infection changes 
gastric mucosa to precancerous pathological stages, 
from atrophic gastritis and IM, ultimately to dysplasia 
and neoplasia. Accordingly, serum pepsinogen I (PGI), 
produced mainly by chief cells in gastric body mucosa will 
decrease significantly. Another pepsinogen, PGII, which is 
produced by gastric mucosa along with other sources, may 
decrease to a smaller extent or remain unchanged. These 
alterations make serum PGI and PGI/II ratios reliable 
surrogate biomarkers for precancerous lesions.98-100 As a 
marker of gastric atrophy, serum pepsinogen has certain 
drawbacks: limited to intestinal types of GC, small positive 
predictive value because of low GC incidence rates in 
most countries, uncertain sensitivity and specificity due 
to diversity of cut-off points in various studies, and being 
affected by both age and HP infection which disrupts its 
interpretation, are a few of these issues to name.101-103 In 
Iran, the results from studies investigating the role of PGI, 
PGII, and PGI/II ratios in the identification of atrophic 
gastritis are contradictory. In a study exploring these 
biomarkers in high (Ardabil) and low (Kerman and Yazd) 
risk populations for GC, the mean serum levels of both 
PGI and PGII, as well as their ratio (≤3), did not differ 
significantly between these regions.101 It was therefore 
concluded that these biomarkers are probably not sensitive 
predictors of atrophic gastritis. However, it was indicated 
in another study from Northeastern Iran that the PG I/
II ratio with a threshold level of <5 can be a relatively 
good marker of fundic atrophy, particularly among those 
with nonatrophic pangastritis.103 Additionally, PGII had 
potential sensitivity to detect the extension of nonatrophic 
gastritis to the corpus. Future studies will better delineate 
the utility and limitations of these biomarkers.
Ghrelin: Our study, together with those by others, 
introduced serum ghrelin as a new screening biomarker 
having an inverse correlation with GC and its precancerous 
lesions, e.g. atrophic gastritis.104-106 In Ardabil, we observed 
that individuals with the lowest quintile of serum ghrelin 
were 8.71- and 6.58-folds more likely to have cardia and 
non-cardia GC, respectively, compared to the highest 
quintile.104 Ghrelin is a peptide produced by P/D1 cells in 
oxyntic glands of the stomach with potential therapeutic 
effect; so, it can potentially detect any histological changes 
leading to GC.107
DNA methylation: Disruption of epigenetic processes 
can lead to malignant cellular transformation. DNA 
methylation, which is the most common and important 
phenomenon of epigenetics in GC, can be targeted for 
early GC detection and predicting its prognosis.108 To 
monitor the progression of gastric precancerous lesions, 
DNA methylation of AMPH, PCDH10, RSPO2, SORCS3, 
and ZNF610 may be helpful.109
Other biomarkers: Another candidate for the GC 
screening might be gastrin-17, which is also used to 
develop anti-gastrin vaccines for GC prevention.110 Other 
convincing biomarkers of either atrophic or inflammatory 
conditions of the gastric mucosa are anti-CagA antibody, 
anti-parietal cells antibody, Trefoil factor family protein, 
and IgG anti-HP antibody.111,112
Further well-powered, long-term studies are required to 
ascertain an optimal serum marker and its cut-off points 
with sufficient sensitivity, specificity, and predictive values 
for routine use in GC screening.
Preventive HP Eradication
As an essential risk factor for GC, HP is classified as a class 
I carcinogen by the IARC.113 Hence, HP eradication seems 
one of the most reasonable preventive strategies against 
GC,114 supported by the Maastricht V consensus.115 The 
ideal way for HP eradication in high-risk regions appears 
to be an active prophylactic immunization of children; 
however, there is no commercial vaccine available yet.116,117 
Hence, massive therapeutic eradication of HP in children 
and young adults seems to be the method of choice at the 
moment. In this context, a protective relative risk of 0.65 
for GC was estimated among treated patients in a meta-
analysis of six studies.118 However, the emerging data 
question this statement.119 In another meta-analysis of 
limited, moderate-quality trials, no evidence of an effect 
on all-cause mortality was observed for HP eradication 
in healthy asymptomatic infected patients.120 Therefore, 
the screen-and-treat strategy for HP infection “needs 
more experience from different geographical areas and 
faces several shortcomings”.121 Moreover, large-scale 
HP eradication in endemic populations like Iran is 
almost impractical for several reasons, including heavy 
expenses and the development of multi-drug resistant 
microorganisms.
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Based on our results from the Ardabil cohort study, we 
tend to agree with Wang et al that the GC incidence could 
be delayed rather than prevented by HP eradication.119 
We also believe that the value of regular early endoscopic 
screening in preventing GC is much greater than anti-
HP therapy. Just like endoscopy, anti-HP therapy may be 
appropriate as a preventive strategy in determined high-
risk groups, not at provincial or national levels.
Chemoprophylaxis
In addition to antimicrobial agents used to treat HP 
infection, some other medications have been shown to be 
protective against GC, as well. Since inflammation plays 
an important role in GC development, anti-inflammatory 
drugs, such as aspirin, were among the first to be discussed 
in this setting.122,123 However, controversies still exist.124 
We should be aware that prolonged aspirin use alone 
might damage the gastric mucosa, but its combination 
with proton pump inhibitors could potentially reduce 
injuries.125 Statins are another category of this sort that 
reduce the incidence of GC by inhibiting HP CagA.126 
Although the literature has inconsistent evidence on the 
chemoprophylactic effect of statins on GC,127 a recent 
meta-analysis supports this hypothesis.128 Metformin use 
in diabetic patients has been also associated with reduced 
GC rates,129 although it needs to be further elaborated.130 
Probiotics, hormone replacement therapy, and ursolic 
acid, are other examples of possible interventions.131-133 
Nonetheless, these chemopreventive strategies need to be 
evaluated and confirmed in larger trials.134
Minimizing Risk Factors
In addition to a targeted screening program with a focus 
on early GC detection, some joint efforts have been made 
to control and minimize the attributable risk factors of GC 
and therefore, to reduce its incidence and mortality.135,136 
To illustrate the results of these preventive strategies, the 
annual percent changes in GC mortality rates are about 
3%-4% in the major European countries, 4.3% in South 
Korea, and 3.5% in Japan.137
Defining High-risk Individuals
In order to design an efficient preventive plan, the first 
step is to define the high-risk groups requiring preventive 
measures against GC. Currently, there is no consensus on 
an inclusive definition; nonetheless, individuals with the 
following characteristics might be cautiously considered 
at a higher risk for developing GC138: (a) Demographic 
features: male gender, age of 50 or more, positive family 
history of GC, low socioeconomic status, residence in a 
high-risk region. (b) Life Style: heavy smoking, chronic 
use of hookah, opium abuse, chronic heavy alcohol 
consumption, diets containing excessive salt intake, 
preserved food (smoked or salted), high amounts of 
meat, low amounts of antioxidants, fruits and vegetables. 
(c) Genetic factors: hereditary diffuse GC, familial 
adenomatous polyposis, hereditary non-polyposis 
colon cancer, blood group A, Li-Fraumeni syndrome. 
(d) Pathological features: positive HP infection, gastric 
precancerous lesions, and pernicious anemia.
Conclusion
To conclude, the best results in reducing GC incidence 
and mortality rates on larger scales appear to arise 
from modifying behavioral and environmental risk 
factors, with more attention to region-specific factors. 
It seems that regular endoscopic screening of GC and 
antibiotic chemoprophylaxis for HP eradication are more 
appropriate in high-risk groups with specified criteria, 
although not yet exactly defined. The future propensity 
should particularly include high-efficacy, non-invasive 
genetic and molecular biomarkers, which have shown 
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